Also known as: Acetamide, 2-chloro-, 2-Chloracetamide, BRN 0878191, 2-Chloroethanamide, EINECS 201-174-2 (+1 more)
CAS 79-07-2
Chloroacetamide (CAS 79-07-2) is a chemical substance with GHS signal word Danger; key hazard signal: H361f ***; H301; H317. Key regulatory status: REACH registered, 4 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from ECHA CLP, EPA ToxValDB, EPA CPDat, SCCS, ECHA REACH, ILO ICSC.
Chloroacetamide is prohibited in EU cosmetics but has active industrial GHS classifications (H361f, H301, H317).
CAS, identifiers, formula, and alternate names for the matched substance record.
EU harmonized hazard classification, hazard statements, pictograms, and signal word.
| Hazard Class | H-Statements | Pictograms | Signal |
|---|---|---|---|
| Repr. 2; Acute Tox. 3 *; Skin Sens. 1 | H361f ***; H301; H317 | GHS08; GHS06 | Danger |
International Chemical Safety Card hazard and exposure summary.
| Field | Value |
|---|---|
| GHS Signal Word | DANGER |
| GHS Hazard Statements | Toxic if swallowed Causes mild skin irritation Causes eye irritation May cause allergic skin reaction Suspected of damaging fertility or the unborn child Harmful to aquatic life |
| Short-term Effects | The substance is irritating to the eyes and skin. |
| Long-term Effects | Repeated or prolonged contact may cause skin sensitization. Animal tests show that this substance possibly causes toxicity to human reproduction or development. |
| Routes of Exposure | The substance can be absorbed into the body in hazardous amounts by ingestion. The substance can be absorbed into the body through the skin. |
Industrial and product-use categories associated with this substance.
Inventory, screening, and regulatory list matches from public chemical databases.
| List | Keyword | Source |
|---|---|---|
| active_ingredient; Europe; Pesticides | Commission of the European Communities | CPCat |
| Indirect additives food contact (10/2018) | FDA | United States Food and Drug Administration (FDA) |
| banned; Europe; Personal care | European Commission | CosIng |
| Europe; Personal care | European Commission | CosIng |
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 10 | mg/kg bw/d | - | intravenous | rabbit | Regulatory source |
| 10 | mg/kg bw/day | - | oral | rat | Regulatory source |
| 10 | mg/kg bw/d | - | oral | rat | Regulatory source |
| 20 | - | - | oral | rabbit | Regulatory source |
| 40 | % | - | oral | rabbit | Regulatory source |
| 50 | mg/kg bw/ d | - | dermal | rat | Regulatory source |
| 0.07979 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 0.3661 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 0.01064 | % | Concentration, one positive response | Dermal | Human | NTP ICE skin sensitization |
| 0.03571 | % | Concentration, one positive response | Dermal | Human | NTP ICE skin sensitization |
| =0.705 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB GESTIS DNEL |
| 2R97846T1L | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 17.07 | % | Incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 31.33 | % | Incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 625 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP ICE skin sensitization |
| 968.8 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP ICE skin sensitization |
| 99.73 | ug/cm2 | Induction dose per skin area, 5% incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 283.7 | ug/cm2 | Induction dose per skin area, 5% incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 13.3 | ug/cm2 | Induction dose per skin area, one positive response | Dermal | Human | NTP ICE skin sensitization |
| 27.68 | ug/cm2 | Induction dose per skin area, one positive response | Dermal | Human | NTP ICE skin sensitization |
| =70 | mg/kg bw | LD50 | oral | Rat | NTP ICE acute oral |
| =138 | mg/kg bw | LD50 | oral | Rat | NTP ICE acute oral |
| =275 | mg/kg bw | LD50 | oral | Rat | NTP ICE acute oral |
| =290 | mg/kg bw | LD50 | oral | Rat | NTP ICE acute oral |
| =306 | mg/kg bw | LD50 | oral | Rat | NTP ICE acute oral |
| =221 | mg/kg bw/day | LEL | oral | Rat | ECHA |
| =222 | mg/kg bw/day | LEL | oral | Rat | ECHA |
| =225 | mg/kg bw/day | LEL | oral | Rat | ECHA |
| =341 | mg/kg bw/day | LEL | oral | Rat | ECHA |
| =382 | mg/kg bw/day | LEL | oral | Rat | ECHA |
| =417 | mg/kg bw/day | LEL | oral | Rat | ECHA |
| =3 | mg/kg bw/d | NOAEL | - | - | SCCS Opinion |
| =9.6 | mg/kg bw/day | NOAEL | oral | Rat | ECHA |
| =10 | mg/kg bw/day | NOAEL | oral | Rat | ECHA |
| =10 | mg/kg bw/d | NOAEL | intravenous | rabbit | SCCS Opinion |
| =10 | mg/kg bw/day | NOAEL | oral | rat | SCCS Opinion |
| <12.5 | mg/kg bw/day | NOAEL | oral | Rat | ECHA |
| =16.6 | mg/kg bw/d | NOAEL | oral | rat | SCCS Opinion |
| =20 | - | NOAEL | oral | rabbit | SCCS Opinion |
| =24 | mg/kg bw/d | NOAEL | - | - | SCCS Opinion |
| =35 | mg/kg | NOAEL | oral | - | SCCS Opinion |
| =40 | % | NOAEL | oral | rabbit | SCCS Opinion |
| =50 | mg/kg bw/day | NOAEL | dermal | Rat | ECHA |
| =50 | mg/kg bw/d | NOAEL | dermal | - | SCCS Opinion |
| =50 | mg/kg bw/ d | NOAEL | dermal | rat | SCCS Opinion |
| =100 | ppm | NOAEL | oral | Rat | ECHA |
| 3 | unitless | Relative reliability score | Dermal | Human | NTP ICE skin sensitization |
| 50 | mg/kg bw/d | dermal absorption | dermal | - | Regulatory source |
| 50 | mg/kg bw/d | dermal absorption | dermal | rabbit | Regulatory source |
| 10 | mg/kg bw/d | genotoxicity | oral | - | Regulatory source |
Showing 50 of 59 studies
Registration status from the ECHA REACH registered substances database.
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | 2-chloroacetamide | 201-174-2 | ECHA overview → |
EU Scientific Committee opinions tied to the matched substance.
| Opinion | Date | Conclusion | Max Conc. | Concerns |
|---|---|---|---|---|
| SCCS/1432/11 | 22 March 2011 | Not safe — not safe under current use conditions | Not safe at 0.3% (current permitted level) | Genotoxicity potential; skin sensitization; insufficient margin of safety at authorised level |
| SCCS/1360/10 | 2011-03-22 | On the basis of the data available, the SCCS comes to the conclusion that 2-chloroacetamide is not safe for consumers when used under the current use conditions of 0.3% in cosmetic products. Human data demonstrate that allergic reactions can be elicited at concentrations lower than 0.3% (use conditions in cosmetics products). | 0.3% | Human data demonstrate allergic (sensitising) reactions can be elicited at concentrations lower than the 0.3% in-use level; classified Repr. Cat 3, Acute Tox 3, Skin Sens 1. |
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
Chloroacetamide (CAS 79-07-2) is classified under EU CLP Annex VI as Repr. 2; Acute Tox. 3 *; Skin Sens. 1 with signal word Danger. Hazard statements: H361f ***; H301; H317. Source: EU CLP Annex VI (ECHA).
Chloroacetamide has 59 NOAEL studies in the database. The lowest reported value is 0.01064 % via Dermal in Human. Source: NTP ICE skin sensitization.
Chloroacetamide appears on 4 regulatory/inventory lists including active_ingredient; Europe; Pesticides, Indirect additives food contact (10/2018), banned; Europe; Personal care, and 1 more. Source: EPA CPDat.
Yes, Chloroacetamide is also indexed as a cosmetic ingredient under the name Chloroacetamide. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from ECHA CLP Annex VI, EPA ToxValDB, EPA CPDat, EPA DSSTox, ECHA REACH, ILO/WHO ICSC, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
Chloroacetamide is prohibited in EU cosmetics but has active industrial GHS classifications (H361f, H301, H317).
Chloroacetamide also appears in cosmetics, pharmaceutical databases.